ΑMT - PsychonautWiki
Open main menu
Summary sheet: ΑMT
ΑMT
ΑMT.svg
Chemical Nomenclature
Common names AMT, αMT, Indopan
Substitutive name α-Methyltryptamine, alpha-methyltryptamine
Systematic name 2-(1H-indol-3-yl)-1-methyl-ethylamine
Class Membership
Psychoactive class Entactogen / Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 5 mg
Light 10 - 25 mg
Common 25 - 40 mg
Strong 40 - 60 mg
Heavy 60 - 80 mg
Duration
Total 13 - 15 hours
Onset 60 - 180 minutes
Peak 4 - 6 hours
After effects 1 - 5 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
alcohol
caffeine
cannabis
Arrayc-t-x
Arrayc-x
5-meo-xxt
amphetamines
cocaine
dox
dxm
maois
mdma
mescaline
mxe
nbomes
pcp
ssris
tramadol


α-Methyltryptamine (also known as Indopan and commonly as αMT or aMT) is a lesser-known entactogen substance of the tryptamine class.[1]

αMT was originally developed by Upjohn in the 1960s.[2] It was briefly used in the Soviet Union as an antidepressant under the trade name Indopan.[1][3][4][5] Indopan was prescribed in 5-10 mg doses, which is significantly lower than the dose used for recreational effects.

Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion."[6] There were 22 deaths linked to αMT in England and Wales where the drug became popular as a legal high from 2012 until it was banned in early 2015.[7]

Limited data exists about the pharmacological properties, metabolism, and toxicity of aMT, and it has a limited history of non-medical human use. It is highly advised to use harm reduction practices if using this substance.

Contents

Chemistry

αMT, or α-Methyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon Rα of its tryptamine backbone with a methyl group.

AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers.

Pharmacology

Further information: Serotonergic psychedelic

αMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist.

αMT also acts as a releasing agent of serotonin, noradrenaline, and dopamine.[8][9] It also acts as a very weak, non-selective RIMA in-vitro[10] and in-vivo.[11], but this is unlikely to be very significant (if at all) with common doses.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.

Physical effects
 

Visual effects
 

Cognitive effects
 

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

The toxicity and long-term health effects of recreational αMT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because AMT is a research chemical with very little history of human usage.

As a monoamine reuptake inhibitor, αMT can be dangerous when taken in excessive doses or when combined with MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of serotonin and dopamine. There is one reported death from AMT, but it is not known how much of the substance was taken.[12] Erowid states that they have received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."[6]

It is worth noting that αMT's analog αET has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.[13] It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long-term use.

Anecdotal reports suggest that there are no negative health effects attributed to simply trying aMT by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

AMT is considered to be moderately habit-forming.

Tolerance to the effects of αMT are built almost immediately after ingestion. After that, it takes about 14 days for the tolerance to be reduced to half and 1 month to be back at baseline (in the absence of further consumption). AMT presents cross-tolerance with all psychedelics, meaning that after the consumption of αMT all psychedelics will have a reduced effect.

Dangerous interactions

Deaths from αMT are rare[6][12] but, as a powerful monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with substances such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.[14]

  • alcohol - aMT has a broad mechanism of action in the brain and so does alcohol so the combination can be unpredictable
  • caffeine - High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating the combination may cause some physical discomfort.
  • cannabis
  • 2c-t-x
  • 2c-x
  • 5-meo-xxt
  • amphetamines
  • cocaine
  • dox
  • dxm
  • maois - aMT is an MAOI on its own. Using enzyme inhibitors can greatly reduce predictability of effects.
  • mdma
  • mescaline
  • mxe
  • nbomes
  • pcp
  • ssris
  • tramadol

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Australia: AMT is illegal to possess, produce and sell.[citation needed]
  • Austria: AMT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Canada: Canada has no mention of this substance in the Controlled substances and Substances Act.[15]
  • Germany: AMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[16] as of January 31, 1993.[17] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[18]
  • Greece: AMT is illegal to possess, produce and sell.[citation needed]
  • Japan: AMT is illegal to possess, produce and sell.[citation needed]
  • Latvia: AMT is a Schedule I drug.[19]
  • Russia: AMT is illegal to possess, produce and sell.[citation needed]
  • Sweden: AMT is illegal to possess, produce and sell.[20]
  • Switzerland: AMT, along with AET are controlled substances specifically named under Verzeichnis D.[21]
  • United Kingdom: AMT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[22]
  • United States: AMT is a Schedule I drug.[23]

See also

External links

References

  1. 1.0 1.1 Shulgin, Alexander; Shulgin, Ann (1997). "#48. a-MT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  2. "US Patent 3296072 - Method of Treating Mental Depression". Google Patents. Retrieved July 18, 2020. 
  3. Donald G. Barceloux (March 20, 2012). Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 196–. ISBN 978-0-471-72760-6. 
  4. Leslie Iversen (November 11, 2013). Handbook of Psychopharmacology: Volume 14 Affective Disorders: Drug Actions in Animals and Man. Springer Science & Business Media. pp. 132–. ISBN 978-1-4613-4045-4. 
  5. Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders. Academic Press. 17 May 2013. pp. 632–. ISBN 978-0-12-398360-2. 
  6. 6.0 6.1 6.2 "AMT (Alphamethyltryptamine, IT-290) - Fatalities / Deaths". Erowid. Retrieved July 18, 2020. 
  7. "Deaths related to drug poisoning, England and Wales". Office for National Statistics. August 15, 2019. Retrieved July 18, 2020. 
  8. Nagai, F.; Nonaka, R.; Kamimura, K. S. H. (March 22, 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2-3): 132–137. doi:10.1016/j.ejphar.2006.11.075. eISSN 1879-0712. ISSN 0014-2999. OCLC 01568459. PMID 17223101. 
  9. Nonaka, R.; Nagai, F.; Ogata, A.; Satoh, K. (December 2007). "In Vitro Screening of Psychoactive Drugs by [35S]GTPγS Binding in Rat Brain Membranes". Biological and Pharmaceutical Bulletin. 30 (12): 2328–2333. doi:10.1248/bpb.30.2328. eISSN 1347-5215. ISSN 0918-6158. OCLC 27784830. PMID 18057721. 
  10. Arai, Y.; Toyoshima, Y.; Kinemuchi, H. (1986). "Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine". The Japanese Journal of Pharmacology. 41 (2): 191–197. doi:10.1254/jjp.41.191. ISSN 1347-8613. PMID 3747266. 
  11. Greig, M. E.; Walk, R. A.; Gibbons, A. J. (October 1959). "The effect of three tryptamine derivatives on serotonin metabolism in vitro and in vivo". Journal of Pharmacology and Experimental Therapeutics. 127 (2): 110–115. eISSN 1521-0103. ISSN 0022-3565. OCLC 1606914. PMID 13851725. 
  12. 12.0 12.1 Boland, D. M.; Andollo, W.; Hime, G. W.; Hearn, W. L. (July 1, 2005). "Fatality due to acute alpha-methyltryptamine intoxication". Journal of Analytical Toxicology. 29 (5): 394–397. doi:10.1093/jat/29.5.394. eISSN 1945-2403. ISSN 0146-4760. OCLC 02942106. PMID 16105268. 
  13. Huang, X. M.; Johnson, M. P.; Nichols, D. E. (July 23, 1991). "Reduction in brain serotonin markers by α-ethyltryptamine (Monase)". European Journal of Pharmacology. 200 (1): 187–190. doi:10.1016/0014-2999(91)90686-k. eISSN 1879-0712. ISSN 0014-2999. OCLC 01568459. PMID 1722753. 
  14. Gillman, P. K. (October 1, 2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  15. "Controlled Drugs and Substances Act - Schedule I". Isomer Design. Retrieved July 18, 2020. 
  16. "Betäubungsmittelgesetz (BtMG) Anlage I" [Narcotics Act (BtMG) Schedule I] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  17. "Vierte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 1992 Teil I Nr. 61 (in German). Bundesanzeiger Verlag [Federal Gazette] (published December 31, 1992). December 23, 1992. p. 1058. eISSN 0344-7634. 
  18. "Betäubungsmittelgesetz (BtMG) § 29" [Narcotics Act (BtMG) § 29] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  19. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  20. "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF) (in Swedish). October 16, 2019. Retrieved July 18, 2020. 
  21. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  22. "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020. 
  23. "ALPHA-METHYLTRYPTAMINE" (PDF). Drug Enforcement Administration. April 2013. Archived from the original (PDF) on January 28, 2016. Retrieved July 18, 2020.